|
Session 31
Symposium
T-Cell Based Vaccines: Promise of Clinical Efficacy?
Tuesday, 2 - 3:30 pm
Room: West Hall B |
| 95 |
How Can T-cell-based Vaccines Protect against SIV and HIV?
Mario Roederer
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US |
| 96 |
Global Epidemiology of HIV: Risk Factors, Social Networks, and Inter-subtype Recombinant Strains in Vaccine Trial Sites
Francine McCutchan*1, G Kijak1, S Tovanabutra1, E Sanders-Buell1, C Beyrer2, M deSouza3, M Arroyo3, M Robb1, D Birx1, and N Michael
Michael1
1US Military HIV Res Prgm, Rockville, MD, US; 2Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; and 3Armed Forces Inst of Med Sci, Bangkok, Thailand |
| 97 |
How Can the Immunogenicity of pDNA Vaccines be Improved?
Michael Egan*1, M Sidhu1, D Weiner2, G Pavlakis3, I Mathieson4, R Kjeken4, and J Eldridge1
1Wyeth Res, Pearl River, NY, US; 2Univ of Pennsylvania, Philadelphia, US; 3NCI-Frederick, MD, US; and 4Inovio Biomed Corp, San Diego, CA, US |
| 98 |
Strategies to Overcome Pre-existing Vector-specific Immunity
Dan Barouch
Beth Israel Deaconess Med Ctr, Boston, MA, US |
|
